Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $22.50.

Several research analysts have recently weighed in on the stock. D. Boral Capital began coverage on shares of Omeros in a report on Monday. They set a “buy” rating and a $36.00 price objective for the company. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a report on Thursday, November 14th.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently modified their holdings of the company. Cypress Capital Group increased its stake in Omeros by 40.0% in the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares during the period. Rhumbline Advisers grew its position in shares of Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 6,435 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Omeros during the second quarter worth about $105,000. Finally, SG Americas Securities LLC bought a new stake in Omeros during the 3rd quarter valued at approximately $80,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $10.31 on Monday. The firm has a market cap of $597.46 million, a price-to-earnings ratio of -4.46 and a beta of 1.97. The business has a 50-day simple moving average of $7.09 and a two-hundred day simple moving average of $5.20. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.